, Montr al, Canada The large majority of biopharmaceutical products are pharmaceuticals that are derived from life forms. Small molecule drugs are not typically regarded as biopharmaceutical in nature ... pharmaceutical products. Research and development investment in new medicines by the biopharmaceutical industry stood at 65.2bn in 2008. ref cite web author BriskFox Financial title Biopharmaceutical ... q1 do v c44751.php accessdate 2009 03 11 ref When a biopharmaceutical is developed, the company will typically ... means by which the developer of the drug can recover the investment cost for development of the biopharmaceutical ... patent applications. ref cite web author Luke Foster title Patenting in the Biopharmaceutical Industry&mdash ... issues. Biopharmaceutical crops also represent a risk of cross contamination with non engineered ... of a transgenic mammal that can produce the biopharmaceutical in its milk or blood or urine ... more details
Alkermes may refer to Alkermes company , a biopharmaceutical company Alchermes , a red liqueur coloured by inclusion of the insect Kermes vermilio See also Kermes disambiguation disambig ... more details
Basilea is the Italian language Italian and Romansh language Romansh name for Basel , Switzerland s third most populous city. Basilea may also refer to 2033 Basilea , a main belt asteroid Basilea Pharmaceutica , a Switzerland based biopharmaceutical company Basilea Schlink 1904 2001 , German religious leader disambig Category Given names de Basilea it Basilea disambigua ... more details
Nanobiopharmaceutics is an inter disciplinary field involving delivery of biopharmaceutical products through nanobiotechnology applications like nanoparticles , liposomes . It involves knowledge from nanobiotechnology , biotechnology and biopharmaceutics. See also Biopharmaceutics Nanomedicine Category Nanotechnology Category Pharmaceutical industry ar nano tech stub pharm stub ... more details
Unreferenced date September 2008 Infobox Company company name Halozyme Therapeutics logo Image Halozyme Therapeutics Logo.gif company type Public company Public nasdaq HALO company slogan foundation 1998 location San Diego, California , United States USA key people Jonathan E. Lim , President & CEO num employees 130 industry Biopharmaceutical products biologic medical product Biologic s revenue profit 3,799,521 United States dollar USD 2007 homepage http www.Halozyme.com www.halozyme.com Halozyme Therapeutics , based in San Diego, California , is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology , oncology , dermatology and drug delivery markets. http www.halozyme.com Category Companies in the NASDAQ Biotechnology Index Category Companies based in San Diego, California ... more details
Orphan date February 2009 Primarysources date February 2011 China Biologic Products, Inc. , through its indirect majority owned subsidiary Shandong Taibang , is the only blood plasma based biopharmaceutical company approved by the government of Shandong Province , the second largest province in China with a population of 93 million. The company is engaged in research, manufacturing, and sale of plasma based biopharmaceutical products to hospitals in China hospitals and other Health care in China health care facilities in China . Plasma based human albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and Therapy treatment . External links http www.ctbb.com.cn Company website Category Companies based in Shandong ... more details
Orphan date February 2009 Ludger Ltd http www.ludger.com is a biotechnology company with R&D and manufacturing facilities at the Culham Science Centre, Oxford , UK ref http www.culham.org.uk news press office article detail.asp?Article ID 1010 ref . The company specialises in technology for the measurement and control of biopharmaceutical glycosylation . ref http archive.oxfordmail.net 2008 5 23 246339.html ref The company was founded in 1999 by its Chief Executive, Dr Daryl Ludger Fernandes. Dr Fernandes had developed glycoprofiling technology for his doctorate in the Glycobiology Institute at the University of Oxford and in the late 1980s was responsible for transfer of that technology to Oxford GlycoSciences OGS . In 2000, the company won a UK Department of Trade and Industry United Kingdom Department of Trade and Industry DTI Smart award to develop biopharmaceutical glycoanalysis technology. ref http archive.oxfordmail.net 2000 4 17 78650.html ref in 2001, it won a UK DTI Link grant for a collaborative R&D project to develop rapid glycoanalysis technology with GlaxoSmithKline and the University of Oxford. The company s focus is to provide products, services for characterization and quality control of biopharmaceutical glycosylation. Current products include kits and reagents for detailed analysis of N linked and O linked glycan s by High performance liquid chromatography HPLC and mass spectrometry . Current services include contract glycosylation analysis to support biopharmaceutical development and regulatory submissions to the U.S. Food and Drug Administration and European Medicines Agency , glycoprofiling method development, and training in biopharmaceutical glycoprofiling procedures. The key glycoprofiling modules include monosaccharide analysis, sialic acid analysis to determine relative levels of human vs non human sialylation, oligosaccharide profiling, and detailed glycan structure analysis. References Reflist Category Biotechnology companies of the Unit ... more details
Unreferenced stub auto yes date December 2009 The biopharmacology is the branch of pharmacology that studies the use of biotechnology biotechnologic originated drug s biopharmaceutical s . See also Pharming genetics Pharming Category Biotechnology Category Pharmacology Biotech stub ar ca Biofarmacologia de Pharmazeutische Biotechnologie es biofarmacolog a ru sl Farmacevtska biotehnologija zh ... more details
Wiktionary Melior may refer to Schools Melior Community College in Scunthorpe in the North Lincolnshire, England Melior International College , International College Singapore Melior Business School , part of Melior Education Group, which has its headquarters in Singapore Other uses Melior typeface , created by Hermann Zapf Melior Discovery , a private biopharmaceutical company based in Exton, Pennsylvania, USA Meilor, a brand name for a french press coffee maker disambiguation ... more details
Infobox company company name Zistdaru Danesh Ltd. company logo Image Zistdaru danesh.jpg 110px location Tehran , Iran products Biopharmaceutical s homepage http www.zistdaru.ir Home.html www.zistdaru.ir Zistdaru Danesh Ltd. also Zist Daru Danesh Ltd. is a private pharmaceutical company which is located in the Pharmaceutical Incubator of the Tehran University of Medical Sciences and is active in the development, manufacturing and marketing of biopharmaceutical s. The company is one of the leading manufacturer of biosimilar products in Iran. ref http www.zistdaru.ir Home.html Zistdaru Danesh Co. Ltd. ref Zistdaru Danesh is manufacturer of the active pharmaceutical ingredient of interferon beta 1b which has been marketed as ZIFERON . interferon beta 1b has been approved to treat relapsing remitting and secondary progressive multiple sclerosis using a 8 million units 250 micrograms vial on alternate days by subcutaneous injection. ref cite news title Iran Starts Mass Production of MS Drug url http english.farsnews.com newstext.php?nn 8906280807 date 2010 09 19 ref ref cite news title Iran Starts Mass Production of MS Drug url http www.presstv.ir detail 143010.html date 2010 09 18 ref See also Interferon beta 1b Interferon References reflist External links http www.zistdaru.ir Home.html Zistdaru Danesh Category Pharmaceutical companies of Iran fa ... more details
Profound Pharma A S was a Danish company that discovered and developed 2nd generation biopharmaceutical s. History Created in Denmark in 1999 by Christian Karsten Hansen and Jan M ller Mikkelsen, formerly of Novo Nordisk , the company was funded by venture capital and a loan from V kstfonden. After rapidly growing to employ 50 scientists, and filing large numbers of patent applications, the company was acquired by Maxygen in 2000 for 60 mill. in stock. ref cite news title Maxygen to Acquire ProFound Pharma A S to Expand its Position in Protein Pharmaceuticals http www.maxygen.com newsview.php?listid 124 ref From its acquisition by Maxygen until 2008, the company continued as a subsidiary of Maxygen forming the cornerstone of its biopharmaceutical business, and contributing to Maxygen s molecular breeding technology. With NeuroSearch , Genmab and Zealand Pharma, Profound Pharma was among the early members of the Medicon Valley biotech cluster. Its initial directors were Dr. Claus Br strup, Prof. Thue Schwartz and Knud Aunstrup. Projects Profound Pharma developed improved versions of interferon type I interferon beta , granulocyte colony stimulating factor , TNF inhibitor s, factor VII and other commercially important protein pharmaceuticals. Technologies Profound Pharma used a variety of protein engineering and protein modification technologies including site directed mutagenesis , rational design, PEGylation , glycosylation , and de immunization. These technologies complemented the molecular breeding technology of Maxygen . References references Category Pharmaceutical companies of Denmark ... more details
Unreferenced date December 2009 A bioprocess is any process that uses complete living cell biology cells or their components e.g., bacteria , enzyme s, chloroplast s to obtain desired products Transport of energy and mass is fundamental to many biological and environmental processes. Areas, from food processing to thermal design of building to biomedical devices to pollution control and global warming , require knowledge of how energy and mass can be transported through materials mass,momentum,heat transfer See also Good Manufacturing Practice Good clinical practice Adverse Drug Reaction Adverse event Assay sensitivity Biopharmaceutical networking Biotechnology Caco 2 Clinical study design Germany Category Biotechnology Med stub Biology stub ar es bioproceso ... more details
notability companies date March 2011 Sunesis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecular therapeutics for oncology and other unmet medical needs. The company was founded by Jim Wells pharmaceutical executive Jim Wells ref http findarticles.com p articles mi m4PRN is 2003 July 29 ai n27640059 ref , ref http cancer.ucsf.edu people wells james.php UCSF Helen Diller Family Comprehensive Cancer Center People James A. Wells, PhD Bot generated title ref . Founded in 1998, Sunesis filed and completed an IPO in 2005. It is listed on NASDAQ as SNSS. http www.shareholder.com visitors print release.cfm?releaseid 191204 External links http www.sunesis.com Sunesis Web Site References Reflist US company stub Category Biopharmaceuticals Category Oncology Category Pharmaceutical companies of the United States ... more details
VPM may refer to Value Process Management Varying Permeability Model Vampire Princess Miyu Ventral posteromedial nucleus , a nucleus of the thalamus part of the brain. Virtual Post Mail Virtual Product Management Vranken Pommery Monopole Variation Point Modeling Computer science Vakzine Projekt Management GmbH, a private vaccine and biopharmaceutical development company in Hanover, Germany Vinde, Pleaca, Mori Sell, Leave, Die An motto of the supporters of FC Steaua Bucuresti against the clubs owner George Becali. Long comment to prevent listing on Special Shortpages.......................................................................... disambig de VPM it VPM ... more details
Image BPSA Logo Only Outline.jpg thumb right 200px Logo of the Bio Process Systems Alliance. The Bio Process Systems Alliance BPSA is a biopharmaceutical industry trade group of suppliers of single use components and single use systems for manufacturing processes. It was created in 2006 through an alliance of 26 suppliers. References cite news first Denise last DeTommaso title Disposables Pushing on an Open Door publisher Pharmaceutical Processing pages 8&ndash 9 date April 2006 Category Trade associations business org stub ... more details
Unreferenced auto yes date December 2009 Orphan date February 2009 Ultraz is a Fluoroelastomeric compound developed by Aquasyn specifically for the Biopharmaceutical industry. A base resistant compound with excellent steam resistance, Ultraz performance far exceeds the baselines of EPDM or PTFE. It is typically used as a membrane material in Hygienic Diaphragm Valves . In Biological applications with periodic steam sterilization requirements, Ultraz is the optimal material for the combined temperature resistance of PTFE and the flexibility of EPDM. USP class VI, cytotoxicity and heavy metals tests have been performed with its use in industry for almost ten years. It is low protein binding, flexible and temperature resistant. Category Fluoropolymers Chemistry stub ... more details
Medicago Inc. TSX MDG Quebec City , Quebec , Canada is a publicly traded biotechnology company focused on the development, production and commercialization of protein based biopharmaceutical s vaccines , monoclonal antibodies , biogeneric s etc. by the genetic engineering of plants . Medicago is listed on the Toronto Stock Exchange under the symbol MDG . See also Plant made pharmaceuticals External links Official http www.medicago.com http irap pari.nrc cnrc.gc.ca success medicago e.html Success story NRC site Category Biotechnology companies of Canada canada company stub med company stub ... more details
Single Use Components are the disposable componentry used in an increasingly popular method of pharmaceutical and biologic medical product biologics production. They differ from traditional Biopharmaceutical process components in that they are disposed of after use as opposed to cleaned or CIP d. They can consist of disposable bag containers, tube sets, instrumentation , electrical connectors , filters and disposable valves . Many companies have adopted this platform for its ease of adapting to new product development needs and the flexibility it allows in adjusting to varying product supply and demand. External links http www.colder.com Specialties Bioprocessing BioHome.aspx http www.artesynprocesssolutions.com Category Medical equipment ... more details
Micro flow imaging MFI is a particle analysis technique that uses flow microscopy to quantify particles contained in a solution based on size. This technique is used in the biopharmaceutical industry to characterize subvisible particles from approximately 1 m to 50 m. ref Sharma, Deepak K., Dave King, Peter Oma, and Clark Merchant. Micro Flow Imaging Flow Microscopy Applied to Sub visible Particulate Analysis in Protein Formulations. The AAPS Journal 12.3 2010 455 64. http www.ncbi.nlm.nih.gov pmc articles PMC2895433 pdf 12248 2010 Article 9205.pdf ref References Reflist Category Materials science ... more details
Orphan date February 2009 Infobox Company company name BioImage company logo Image Logo bioimage.png company type Private foundation 1999 location Soeborg, Denmark key people Patrik Dahl n, CEO br Steven Butcher, CSO br Len Pagliaro, VP Business Development br Edwin Moses Chairman of the Board br Axel Ullrich Chairman of the Scientific Advisory Board industry Biotechnology products Products, services, and licensing around the proprietary Redistribution sup TM sup drug discovery technology revenue not available homepage http www.bioimage.com BioImage was established in 1993 as a drug discovery research unit within Novo Nordisk . The research unit was led by Ole Thastrup and spun out of Novo Nordisk in 1999. BioImage specializes in developing and selling proprietary bioassay s to biopharmaceutical companies and research institutions. It also develops bioassays on a contract service basis. BioImage has made broad patent s covering EGFP Enhanced GFP EGFP , GFP based biosensors and any genetically encoded fusion protein protein fusion to a luminophore , with subsequent monitoring of the protein s Protein translocation translocation within a Cell biology cell as the primary readout for drug discovery assays. This intellectual property, trademarked Redistribution, allows many collaborations and out licensing activities with biopharmaceutical companies. ref http www.bioimage.com technology.htm overview technology & applications BioImage Bot generated title ref Merger In April 2006, BioImage was acquired by Thermo Fisher Scientific . The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008. ref http www.bioimage.com pdf CEOletter.pdf ref References reflist Category Companies of Denmark Category Research support companies med company stub Denmark company stub ... more details
Infobox company company name Acadia Pharmaceuticals company logo File Acaida logo.gif company type Public company Public traded as Nasdaq ACAD foundation 1993 founder location San Diego, California San Diego , California CA , United States U.S. area served key people Dr. Uli Hacksell br small Chief Executive Officer CEO small industry Biopharmaceutical products Pimavanserin revenue increase 42.13M small 2011 operating income increase 10.70M small 2011 net income increase 29.14M small 2011 assets equity num employees 27 ref http finance.yahoo.com q pr?s ACAD Profile ACAD Profile ACADIA Pharmaceuticals Inc. Stock Yahoo Finance Bot generated title ref homepage http www.acadia pharm.com http www.acadia pharm.com ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin , which is in Phase III clinical development as a treatment for Parkinson s disease psychosis. It is also developing AGN XX YY, a product candidate in Phase II for chronic pain and AC 262271, a product candidate in Phase I for glaucoma , both in collaboration with Allergan, as well as AM 831, a product candidate in IND track development for schizophrenia in collaboration with Meiji Seika Meiji Seika Kaisha . The product candidates in the company s pipeline emanate from discoveries made using its proprietary drug discovery platform. Recent Events Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and opthalmic conditions. ref http finance.yahoo.com news Acadia Pharma extends eye apf 2862915783.html?x 0&.v 1 Acadia Pharma extends eye drug deal with Allergan ref References Reflist Portal box California Companies Category Companies in the NASDAQ Biotechnology Index Category Pharmaceutical companies of the United States ... more details
notability Companies date January 2012 unreferenced date January 2012 Infobox company company name Werum Software and Systems AG company logo company type foundation 1969 founder Wulf Werum owners location city L enburg location country Germany key people Hartmut Krome Chairman , Rudiger Schlierenkaemper Director , Hans Peter Subel Director industry Information Technology products Software revenue operating income net income num employees 420 30. June 2011 owner parent subsid homepage http www.werum.com footnotes Headquartered in L neburg , Werum Software & Systems AG is one of the largest independent software vendors in Northern Germany. It is the world leading supplier of Manufacturing Executions System MES Software for the Pharmaceutical and Biopharmaceutical industry. CN date February 2012 Company Structure Werum has offices in nine locations globally and has four child organizations Werum Software & Systems AG, Germany Headquarters in L neburg West German office in St. Augustin South West German Office in Hausach Werum Software & Systems SAS, France Office in Toulouse Werum Software & Systems America, Inc., USA Headquarters in Parsippany Parsippany, NJ Regional Office in Cary, North Carolina Cary, NC Regional Office in Pasadena, California Pasadena, CA Werum Software & Systems Pte Ltd., Singapore Office in Singapore Werum Software & Systems K. K., Japan Office in Tokyo Software Products Werum develops software products and solutions in the following fields Manufacturing Execution Systems MES for the pharmaceutical and biopharmaceutical indudtry Test data management software for use in many different fields e.g. Automotive, Aviation, Renewable Energy, etc. Development of customer specific IT solutions in the filds of eGovernment and eBusiness External links http www.werum.com Werum Software & Systems AG References references Category Software companies of Germany de Werum Software & Systems ... more details
Oracle Clinical or O C is a database management system designed by Oracle Corporation Oracle to provide data management, data entry and data validation functionalities to Clinical Trials process. ref cite book last Chow first Sheiu Chung title Encyclopedia of Biopharmaceutical Statistics publisher Informa Health Care date 2003 pages 397 401 url http books.google.co.uk books?id M8S8WVRUIY0C&pg PA398&dq 22Oracle Clinical 22&client firefox a PPA401,M1 isbn 0824742613 ref The Major Functions Supported by Oracle Clinical are Clinical Study Protocol Definition and Management Definition of Metadata collected during a Clinical Study. Creation of Data Entry System Creation of Data Management System to clean and reconcile Data Validation Procedures Data Loading and Extracting Thesaurus Management System for Coding Medical Terms Laboratory Reference Range Management System The cost of oracle clinical software is around one crore in India. References references Category Oracle software ... more details
Unreferenced date December 2006 Tercica, Inc. , is a biopharmaceutical company based in Brisbane, California, USA. It is owned by Ipsen . It is the current developer of Increlex mecasermin rDNA origin injection , also known as recombinant human Insulin like Growth Factor 1 rhIGF 1 . Tercica has applied to the Food and Drug Administration FDA for approval of Increlex as a long term therapy for growth failure in children with severe primary IGF 1 deficiency Primary IGFD , which is characterized by growth faiulre, and as a treatment for children with growth hormone GH gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech , Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD. See also Portal Companies Human growth hormone Human growth hormone HGH IGF 1 Category Companies formerly listed on NASDAQ Category Biotechnology companies biotech stub US corp stub med company stub ... more details
Encyclopedia
top
